Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12602967 | 0.92 | BTK (0.54) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL16415939 | 0.91 | BTK (0.55) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL105830 | 0.90 | BTK (0.52) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL12602965 | 0.89 | BTK (0.51) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL12602921 | 0.89 | BTK (0.53) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL103714 | 0.89 | BTK (0.51) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL12650243 | 0.88 | BTK (0.51) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL12650209 | 0.88 | BTK (0.52) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL104011 | 0.88 | BTK (0.52) | BTKSRCKDM4ERAB9ACLK2 | |
| SCHEMBL103815 | 0.87 | BTK (0.58) | BTKSRCKDM4ERAB9ACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | BTK 1/4885SRC 110/4885KDM4E 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.